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Markov simulation of US pregnant women and infants under 6 months of age for 1 
calendar year, from July 1 through June 30. National statistics on live births and infant 
mortality were used to generate probabilities of delivery and infant death based on 
gestational age. Each week, women entered the cohort with new pregnancies, and left 
by delivery; infants entered by delivery and left by death or reaching 6 months of age. 
Annual inﬂ uenza-attributable rates of outpatient visits and hospitalizations for preg-
nant women and infants were obtained from the literature, and adjusted to weekly 
incidences using CDC data on inﬂ uenza-positive respiratory isolates. In the base case, 
we assumed vaccination would begin in calendar week 40, be administered at routine 
prenatal visits across all gestational ages, and continue throughout the rest of the year, 
with vaccine efﬁ cacy of 73% for prevention of maternal ﬂ u and 63% for prevention 
of ﬂ u in infants under 6 months. Costs and maternal utilities were obtained from 
previously published analyses; we used published parental utilities for relevant infant 
health states. RESULTS: Base-case cost-effectiveness was $65,112/QALY gained. 
Fifty-six percent of the reduction in morbidity was attributable to prevention of disease 
in infants, and all of this beneﬁ t was accrued by vaccination within the ﬁ rst 4 weeks 
of vaccine availability. CONCLUSIONS: Vaccination of pregnant women against 
seasonal inﬂ uenza is cost-effective, with much of the beneﬁ t derived from prevention 
of infant disease. Vaccination is most efﬁ cient when the majority of pregnant women 
are vaccinated within 4 weeks of vaccine availability.
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OBJECTIVES: To evaluate the cost-effectiveness of the combination therapy with 
dutasteride and tamsulosin (D+T) as initiation treatment versus tamsulosin (T), con-
sidered the standard of care, in the treatment of moderate to severe benign prostatic 
hyperplasia (BPH) in Spain. METHODS: A semi-Markov model was developed using 
4-year and 35-year time horizons. Data were obtained from the CombAT and litera-
ture review, and the analysis was made from the National Healthcare Service perspec-
tive. Effectiveness was measured in terms of reduction of acute urinary retention 
(AUR) events and/or BPH-related surgeries and quality adjusted life-years (QALYs). 
Health care resources were deﬁ ned by an experts’ panel, and unitary costs were 
obtained from published Spanish sources and expressed in 2010 Euros. The model 
calculates costs, AURs and/or surgeries, and QALYs related to each therapy. Costs 
and effectiveness outcomes were discounted at 3.0%. One-way and probabilistic 
sensitivity analyses were conducted to test the robustness of the model. RESULTS: 
Combination therapy with D+T improves patients’ outcomes. At 4 years, D+T patients 
have a 9.9% reduction in AURs and/or surgeries over T, reaching 43.9% at 35 years. 
At 4 and 35 years, total costs related to T treatment add up to 1,373.90c and 
5,187.37c, and total costs related to D+T are 2,184.43c and 8,630.99c, respectively. 
Therefore, at 4 years, treatment with D+T presents an additional cost of 81.66c per 
AUR and/or surgery avoided and 14,023.32c per QALY gained compared to T. At 
35 years, results were 79.10c per AUR and/or surgery avoided and 8,750.15c per 
QALY gained. Sensitivity analyses showed that results are robust. CONCLUSIONS: 
Given the assumptions, combination treatment with D+T not only represents a more 
effective alternative versus T due to the reduction in AURs and/or surgeries, but also 
is a cost-effective treatment in patients with moderate to severe BPH in Spain.
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OBJECTIVES: The recently made coverage decisions by UK’s NICE, Scotland’s SMC 
and the allocation of $1.1Billion for comparative effectiveness research by the United 
States, are strong indicators of trends in pricing and reimbursement that are likely to 
be observed in the future. To gain an additional insight into these trends, we analyzed 
the cost-effectiveness studies for the top 10 highest selling drugs (~$80–95B worldwide 
sales). METHODS: The Top 10 drugs were selected based on their worldwide sales. 
For this analysis, we segmented these drugs into categories as primary care, specialty, 
small molecules, biologics, therapy areas and availability of generic alternatives. We 
analyzed the cost-effectiveness studies that were published in peer-reviewed journals. 
Search was conducted using generic names of the drugs and the phrase “cost-effec-
tiveness” in abstract of the published study. RESULTS: During 2003–2008, the 
number of published studies on “cost-effectiveness” have increased by more than 
30%. Almost half of the published studies belong to—Remicade, Plavix and Enbrel. 
There is a large variability in CERs for same drugs for different indications, in some 
cases also varying by biomarkers. Primary care drugs had lower and less variable CERs 
than specialty drugs. Variations also exist in methodology used by different groups in 
modeling cost-effectiveness, especially for time horizon and comparator. Majority of 
primary care drugs were modeled for a time horizon of 35–40 years or lifetime to 
demonstrate cost-effectiveness. Among the top 10 drugs, quetiapine and erythropoi-
etin had the highest variability across different studies, and atorvatstatin, salmetrol/
ﬂ uticasone and clopidogrel had the most consistent ICER values across studies. CON-
CLUSIONS: This analysis shows the range, variability and methods used for calcula-
tion of ICER values for these high budget impact drugs and provides lessons for 
executives and policy makers.
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OBJECTIVES: To assess the cost-effectiveness of the anterior repair of the Pelvic organ 
prolapse (POP) with Prolift® versus the colporrhaphy (COLP), under private payer 
perspective, in Brazil. METHODS: A multi-state Markov model was developed to 
assess the evolution of a patient with anterior vaginal prolapse after COLP and 
Prolift® after 2, 4, 10 and 20 years. a panel of specialist was conducted to obtain the 
local practice and to collect the complication rates. Only direct medical costs were 
considered (SIMPRO, 2010; CBHPM 5th Ed). Clinical data, transition probabilities 
and mortality rates were taken from published sources (IBGE, 2008; Jia, X 2007). 
The base-case patient could face up to three surgical repairs if prolapse relapsed. Two 
scenarios were modeled to compare the clinical and economic impact of Prolift® as 
second line treatment; mesh grant was the assumed third line treatment for both 
scenarios. Discount rate of 5% for costs and outcomes was taken following the Brazil-
ian HTA guidelines (Vianna, 2007). One-way sensitivity analysis was conducted to 
assess the robustness of the results. RESULTS: The total costs for the ﬁ rst year were 
higher for Prolift® (R$8119 versus R$4777; incremental R$3342). For the 2nd year 
the difference in the total costs reduced (R$8659 vs. R$7435; additional R$1223) 
with better outcomes for Prolift® (incremental QALYs: 0.04) with ICER ranging from 
R$19,099 (non discounted) to R$33,207 (discounted). For the next years the ICERs 
reduced, showing long term beneﬁ ts of the adoption of Prolift®. For the fourth year 
ICER ranging from R$419 to R$532, 10th year from R$578 to R$827 and for the 
20th year ranging from R$832 to R$1291, for non discounted and discounted results. 
CONCLUSIONS: Findings suggest Prolift® as a cost-effective intervention, under the 
Brazilian private payer perspective.
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OBJECTIVES: To estimate the cost-effectiveness in relation to the efﬁ cacy of PCV-13 
among elderly (both the total population and those at increased risk) aged 65 years 
and older for the The Netherlands, for various levels of efﬁ cacy assumed. METHODS: 
Our previously published cost-effectiveness model was updated to include, age-speciﬁ c 
epidemiological data and health care utilization and costs for a hypothetical cohort 
of elderly aged over 65 years of the population of the The Netherlands. This cohort 
was followed twice- once as unvaccinated and once as a vaccinated cohort- over a 
time period of 5 years. Outcome measures included costs, life-years (LYs), quality-
adjusted life-years (QALYs) and cost-effectiveness ratios (CERs). All analyses were 
performed from a societal perspective. RESULTS: Vaccination remained well below 
the c80,000 per LY except if the vaccine was only assumed to be protective against 
bacteraemic pneumonia with a relatively low effectiveness (40%) in combination with 
a high vaccine price (c65) and indirect effects of serotype replacement would largely 
offset the direct effect of vaccination. For various assumptions, introduction PCV-13 
(assuming a 60% efﬁ cacy against invasive and non invasive disease due to vaccine 
serotypes, and a cost of c50 per vaccinated person) the incremental cost-effectiveness 
ratio varies over from cost-saving to c50,676 per LY. More probable scenarios gener-
ated cost-effectiveness ratios which would be labeled as cost-effective. CONCLU-
SIONS: In the The Netherlands, vaccination with PCV-13 is likely to be considered 
cost-effective both for the total and for the high-risk population over 65 years of age 
from a societal perspective over a ﬁ ve-year time horizon. The main limitation of this 
study was the uncertainty regarding the share of pneumococcal related pneumonia.
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OBJECTIVES: To assess the cost-effectiveness of various cervical screening strategies 
in a cohort of 12-year-old US women with (V) and without (NV) a human papillo-
mavirus (HPV) 16/18 vaccine with efﬁ cacy against vaccine and non-vaccine oncogenic 
HPV types. METHODS: A lifetime Markov model simulating the progression of HPV 
infection and subsequent cervical disease (cervical intraepithelial neoplasia (CIN), 
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cervical cancer, and death) was developed. Thirty cervical screening strategies were 
investigated, including the American College of Obstetricians and Gynecologists’ 
recommendation: screening women every 2 years starting at age 21 years, increasing 
to 3 years following three consecutive negative tests after age 29 (denoted “21/2–3”). 
Other strategies varied initial screening age (16, 21, or 25 years) and screening fre-
quency before and after age 30 years (every 1, 2, 3, 4, or 5 years). Vaccination was 
assumed to provide 95% efﬁ cacy against CIN2+ due to types 16/18 and 37.4% efﬁ -
cacy against CIN2+ excluding co-infections due to HPV types 16/18 (extrapolated to 
efﬁ cacy against infection). The primary outcome was incremental cost-effectiveness 
ratio (ICER) per quality-adjusted life-year (QALY) gained. Full screening compliance 
and vaccination coverage were assumed; all outcomes discounted at 3% per year. 
RESULTS: The 25/5–5NV strategy (every 5 years starting at age 25 years, without 
vaccination) was least costly. No other screening scenario without vaccination was 
cost-effective. The 25/5–5V strategy was cost-effective compared with the 25/5–5NV 
strategy ($9,000/QALY). Other non-dominated strategies (25/3–4V, 25/2–3V, and 
25/1–2V) produced ICERs above $100,000 per QALY. CONCLUSIONS: Model 
results suggest initiating screening at age 25 with a 5-year frequency in the presence 
of HPV vaccination is cost-effective compared with increasing screening frequency 
without vaccination or lowering the age of screening initiation. Increasing HPV vac-
cination in 12-year-old women would allow for less frequent screening initiated at 
older ages, constituting an efﬁ cient use of health care resources.
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OBJECTIVES: Dutasteride and ﬁ nasteride are indicated for treatment of BPH and 
both agents have demonstrated efﬁ cacy as risk reduction (RR) of PCa. The present 
work assesses the cost-effectiveness of the combined effect of each drug on BPH 
progression and RR of PCa, in the treatment of BPH patients with a risk of developing 
prostate cancer (PSA ≥ 3). METHODS: A previously validated Markov model was 
populated to simulate the cost-effectiveness of treatment with dutasteride or ﬁ nasteride 
in men with BPH and a PSA-level ≥3. Equal effect was assumed of the two drugs on 
BPH progression, and an indirect comparison was performed to compare RR effect on 
PCa for dutasteride (the REDUCE trial) and ﬁ nasteride (the PCPT trial). Due to different 
study design and populations in the two trials, an adjustment was made to the REDUCE 
trial results to match the PCPT trial design. Data on incidence, costs and quality-of-life 
for BPH and PCa were retrieved from registries, publications and expert opinions. The 
outcome is presented as incremental cost per QALY and results were presented in c2009. 
Extensive sensitivity analyses were performed to present the uncertainties in the results. 
RESULTS: Estimated RRR of clinically detectable PCa in REDUCE was 33.3%–73%, 
depending risk level chosen as trigger for detection of PCa, compared to 19% for 
ﬁ nasteride. Incremental cost per QALY gained was estimated at c28,970 with the most 
conservative risk reduction of 33%. Sensitivity analysis gave a range from c4,940 to 
c54,200 per QALY. Results were most sensitive to changes in level of risk-reducing 
beneﬁ t of PCa and quality-of-life weights attributed to the diagnosis of PCa. CON-
CLUSIONS: Use of dutasteride to reduce the risk of PCa and BPH progress is expected 
to be cost-effective compared to ﬁ nasteride when used in 60-year-old men with BPH 
and PSA ≥ 3.
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OBJECTIVES: The aim was to estimate the indirect costs of absenteeism generated 
by women during pregnancy and in post-natal period. The secondary objective was 
to quantify the indirect costs in relation to the maternity beneﬁ ts and examine the 
shares of absenteeism caused by pregnancy, childbirth, and puerperium in a total 
disease-related absenteeism in Poland. METHODS: The indirect costs of pregnancy 
were estimated using human capital approach. Social Insurance Ofﬁ ce reports on the 
disease-related absenteeism in Poland in the years 2006–2008 were used as a data 
source. The sickness beneﬁ ts (equal to wages) were used to estimate the indirect costs 
of monthly absence. Indirect costs were compared with the forecasted production 
value to be generated by a child in a life-time horizon (discounted with a rate of 5%, 
accounting for survival probabilities, changing wages and rate of activity rate). 
RESULTS: The pregnancy, parturition and puerperium related absenteeism repre-
sented in years 2006–2008 successively 15.1%, 15.8% and 16.7% of the total disease-
related absenteeism in Poland. The cost of absenteeism during pregnancy, childbirth 
and puerperium in 2006 amounted to c242 million (1c = approx. 4.10 PLN), and in 
2 successive years increased by an average of c66 million yearly. Indirect cost associ-
ated with maternity leaves in years 2006–2008 amounted to c267.7 million, c341.8 
million, and c441.6 million respectively. The total indirect costs of pregnancy in years 
2006–2008 achieved an average of c651.1 million. The indirect cost related with single 
pregnancy was estimated at c1650 representing only 3.5% of future estimated produc-
tion value generated by a child (c47,083). CONCLUSIONS: However pregnancy is 
obviously not an illness, the indirect costs thereof can be calculated and should be 
used when evaluating the impact of family-friendly policies. The indirect costs are 
negligible comparing to future beneﬁ ts.
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OBJECTIVES: The work absenteeism due to care for a sick person can be considered 
as indirect costs of illness. This study aimed at assessing the global burden of caring 
for the ill on productivity in Poland. METHODS: Data were obtained from a survey 
that incorporated information on a burden of caring for the sick and the WPAI-GH 
questionnaire during computer-assisted personal interview in a representative sample 
of the Polish general population aged more than 15 years. There were 2019 respon-
dents, gathered in two waves in January and May 2010. Human capital approach was 
used with GDP per capita as a measure for the monetary value of a time unit (c4.2 
per hour). RESULTS: The ﬁ nal population comprised 795 employees among whom 
167 respondents (21%) took care for a sick person in the last 12 months—78 (10%), 
74 (9%), and 19 (2%) responders took care for a child, other family member and 
non-family member, respectively. On average a respondent spent 9 hours a day (h/d) 
taking care of a sick person for an average period of 21 days (11 h/d for 14 d caring 
for a child; 7 h/d for 23 d caring for other family member; 13 h/d for 22 d caring for 
non-family member). These 9 hours were reduced working time (3,4 h) and off-work 
activities (5.6 h). Estimated productivity lost equals c303 on average per year for 
individuals looking after the ill and c11 on average per year for each employee. 
CONCLUSIONS: Caring for the sick, mostly family members, inﬂ uences working 
time of Polish employees. Productivity loss of a single employee has a moderate impact 
on production, but in global scale or in speciﬁ c health condition it might be perceived 
as an important factor modifying indirect costs of illness.
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OBJECTIVES: The assessment of individuals’ demand and related costs can guide to 
allocate health care resources and improve access to health care. We created a seg-
mentation demand model and we estimated health care costs and their determinants 
within speciﬁ c and distinguished groups of general population. METHODS: The 
target population included subjects living in an area of northern Italy registered at one 
Local Healthcare Unit in 2005 (1,031,684 subjects). On the basis of clinical judgments 
and literature, we identiﬁ ed eight different segments: subjects unknown to HS, mater-
nity and infancy, elderly, people with one chronic disease (CD), people with more 
CDs, people with probable or not severe CDs, subjects with acute event, healthy 
people. To describe these groups and their health demand, we used demographic and 
health care demand data (hospital admissions, drug’s prescriptions, medical specialist 
visits, diagnostic tests) from administrative databases available at the Lombardy 
Health System (HS). These were merged adopting probabilistic record linkage 
(DENALI Data Warehouse) to optimize correct matching of data. RESULTS: Overall, 
health care cost c834 million in 2005 (c809 per-capita). Healthy people were 53% of 
the sample and cost c180 per-capita. Next more frequent subjects were those with 
one CD (14%) and cost c916 per-capita, then those with more CDs (13%) who cost 
c3457 per-capita. Hospitalizations were the cost driver in 5 segments (maternity and 
infancy, elderly, one CD, more CDs, acute event), accounting for 42–89% of total 
costs. Diagnostic tests and medical visits contributed to 42–45% of total costs among 
healthy subjects and those with probable CD. Drugs accounted for 24% of costs of 
sample. CONCLUSIONS: This pioneer demand segmentation model shows an 
example of how merging different administrative databases makes possible under-
standing effects of their characteristics on health care demand and costs. Research is 
encouraged to improve model and study speciﬁ c variants that can be applied in dif-
ferent health care contexts. 
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OBJECTIVES: Non-adherence to treatment regimens results in risks and health care 
costs due to increased emergency care. One reason for non-adherence, especially with 
multiple prescriptions, may be the lack of coordination of care among multiple special-
ists (Cutler & Everett, 2010). Assuming that general/family practitioners (GPs) help 
coordinate patient care, the current study examined the impact on adherence of visit-
ing a GP. METHODS: Adherence data from the European 2008 National Health and 
Wellness Survey (a self-reported online survey sampling respondents from the UK, 
France, Germany, Italy, and Spain) were analyzed, with ANOVAs or negative bino-
mial regressions (for resource utilization), as a function of seeing a GP (yes/no) crossed 
with number of prescriptions (1–2, 3–4, and 5+). Adherence, the main outcome, was 
a Morisky Score ranging from 0 (perfect adherence) to 4 (low adherence). Health 
care resource utilization measures included number of hospitalizations and visits to 
the emergency room (ER) in the past six months. RESULTS: There were 17,690 
